News and Trends 29 Oct 2019 MorphoSys and Galapagos’ Eczema Drug Abandoned at Phase II Development of MorphoSys, Galapagos, and Novartis’ first-in-class antibody drug has been discontinued during a phase II trial after an interim analysis suggested it wouldn’t meet its main endpoint of reducing eczema symptoms. The drug was being developed to treat the inflammatory skin condition atopic dermatitis, also known as eczema. It arose from a collaboration between […] October 29, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Oct 2019 AI-Driven Antibiotic Susceptibility Test Launched in Austria Ares Genetics, an Austrian subsidiary of the German Curetis Group, has launched an early access program for its AI-driven antibiotic susceptibility test. The company, which focuses on molecular diagnostics, has a large, regularly updated database of genetic information on disease-causing microbes including strains showing antimicrobial resistance. The new test uses high-resolution sequencing to gain genetic […] October 28, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
More News! 28 Oct 2019 UK Company Synthesizes Long DNA Molecules with 85% Accuracy The UK biotech Camena Bioscience has proven it can synthesize long DNA molecules with more accuracy than traditional chemical synthesis. Camena tested its technology’s ability to accurately synthesize DNA molecules with a length of 300 nucleotides — the building blocks of DNA. Using Camena’s technology, 85% of the synthesized DNA molecules were accurate to the […] October 28, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Sponsored 28 Oct 2019 How can Proteomics Boost the Discovery of Novel Drugs and Biomarkers? Proteins, the key players within cells. They carry out enzymatic functions, are involved in signaling cascades, contribute to the structure of cells, and much, much more. Their abundance and intricate functions make the study of the proteome highly complex. However, once decoded, proteins can be highly useful for the discovery and development of novel therapies, […] October 28, 2019 - 8 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
News and Trends 25 Oct 2019 EU Court Ushers in the Use of Phages Against Listeria in Food Amidst recent listeria outbreaks in Europe, the European Court of Justice has issued a court order in favor of the company Micreos Food Safety allowing the use of its phage technology to keep listeria at bay in food. Bacteriophages, or phages for short, are viruses that only kill specific bacterial strains and are harmless to […] October 25, 2019 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Startup Scout 25 Oct 2019 This UK AI Tool Researches Diseases for Drug Discovery Companies The Manchester-based company Biorelate is developing artificial intelligence (AI) technology that can collect biological data from the internet and speed up the drug discovery process. Mission: Develop AI technology that trawls the web for disease and drug data and collects it together like researchers would do manually in drug discovery. Biorelate’s product is able to […] October 25, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2019 British AI Firm Gets €9M Boost to Develop Drug-Discovery Tech London-based LabGenius has secured €8.9M in Series A funding, which the company plans to use to scale up its AI- and robotics-based drug development technology. LabGenius focuses on developing protein-based therapeutics using its ‘robot scientist’ EVA. “By transforming how these drugs are discovered, we have a shot at improving the lives of countless people,” said […] October 24, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2019 German Alzheimer’s Drug Backed with €43M After Biogen’s Surprise Turnaround The German company Vivoryon Therapeutics has raised €43M on Euronext Amsterdam to fund a phase IIb trial of a drug that could slow the progression of Alzheimer’s disease by blocking toxic forms of the protein amyloid-beta. Vivoryon Therapeutics, previously known as Probiodrug, raised the money using a rights offering and a private placement on Euronext […] October 24, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 23 Oct 2019 Channeling the Power of AI into Personalizing Medicine Artificial intelligence has been much discussed of late, but will it really help us solve important problems like how to bring personalized medicine to as many patients as possible? Kate Hilyard, COO of Healx in Cambridge in the UK, believes it can. Getting a drug to clinical trials currently requires a large investment of both […] October 23, 2019 - 7 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 22 Oct 2019 Austrian Biotech Will Develop Viral Protein For Vaginal Infection The Austrian biotech company PhagoMed Biopharma is developing a viral protein that could one day treat the common condition bacterial vaginosis without disrupting the microbiome as traditional antibiotics do. The preclinical drug candidate is derived from a protein called an endolysin. Endolysins are made by bacteria-hunting viruses called bacteriophages and kill bacteria by rupturing the […] October 22, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 21 Oct 2019 Update: Abivax’s Ulcerative Colitis Drug Effective Long-Term Update (21/10/2019): An extension of French biotech Abivax’s phase IIa trial shows its treatment for the inflammatory bowel disease ulcerative colitis has good efficacy after a year of treatment, with 75% of the screened patients remaining symptom-free. Of the 32 patients in the original phase IIa trial, 19 patients were treated with Abivax’s drug in […] October 21, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Startup Scout 18 Oct 2019 This Biotech Fights Autoimmune Disease with Rare Immune Cells We come to the biotech hub of Paris, France, where the biotech Ermium Therapeutics is developing treatments for autoimmune diseases that don’t suppress the whole immune system as current treatments do. Mission: To develop small molecule drugs for autoimmune conditions such as lupus by selectively blocking the activity of a rare type of immune cells […] October 18, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email